China’s first new crown mRNA vaccine was approved for clinical use, and Watson biology and Suzhou biomedical enterprises participated in the joint development

“Suzhou released” novel coronavirus mRNA vaccine (ARCoV), which was jointly developed by Suzhou Abbott biotech Co., Ltd., joint military academy of Sciences, and Yunnan Watson biotechnology Limited by Share Ltd in June 26th, was approved by the State Drug Administration and Supervision Bureau in June 19th. This is the first mRNA vaccine approved to carry out clinical trials in China, and also the first mRNA vaccine to enter clinical trials after the completion of animal attack experiments in the world.